Xin Lang Cai Jing·2025-11-07 01:36Group 1 - The core viewpoint of the news is that Guangdong Wannianqing Pharmaceutical Co., Ltd. is experiencing a decline in stock performance and financial metrics, with significant changes in financing activities and shareholder structure [1][2]. Group 2 - On November 6, Guangdong Wannianqing's stock price fell by 1.61%, with a trading volume of 30.78 million yuan. The financing buy-in amount was 2.14 million yuan, while the financing repayment was 4.38 million yuan, resulting in a net financing buy of -2.23 million yuan [1]. - As of November 6, the total balance of margin trading for Guangdong Wannianqing was 51.48 million yuan, which accounts for 1.88% of its circulating market value, indicating a low financing balance compared to the past year [1]. - The company had no short-selling activities on November 6, with a short-selling balance of 0.00 yuan, which is at a high level compared to the past year [1]. - As of September 30, the number of shareholders for Guangdong Wannianqing was 11,400, a decrease of 7.18% from the previous period, while the average circulating shares per person increased by 7.74% to 13,994 shares [2]. - For the period from January to September 2025, Guangdong Wannianqing reported an operating income of 228 million yuan, a slight decrease of 0.14% year-on-year, and a net profit attributable to shareholders of -8.13 million yuan, a significant decrease of 157.65% year-on-year [2]. - Since its A-share listing, Guangdong Wannianqing has distributed a total of 65.6 million yuan in dividends, with 40 million yuan distributed over the past three years [2].